An Open Label Trial of Dianhydrogalactitol (VAL-083) and Radiation Therapy in Treatment of Newly Diagnosed GBM Patients With An Unmethylated Promoter of the Methylguanine-DNA Methyltransferase (MGMT) Gene
Phase of Trial: Phase II
Latest Information Update: 17 Apr 2018
At a glance
- Drugs Dianhydrogalactitol (Primary)
- Indications Glioblastoma
- Focus Therapeutic Use
- Sponsors Del Mar Pharmaceuticals
- 17 Apr 2018 According to a DelMar Pharmaceuticals media release, dose-confirmation (n=4) studying 20 and 30 mg/m2/day cycles has been completed.
- 17 Apr 2018 According to a DelMar Pharmaceuticals media release, data from this trial will be presented at the American Association for Cancer Research (AACR) Annual Meeting (2018).
- 21 Nov 2017 According to a DelMar Pharmaceuticals media release, an overview of the trial design has been presented at the 22nd Annual Meeting and Education Day of the Society for Neuro-Oncology (SNO).